Open | $2.250 |
Close | $2.250 |
Volume / Avg. | 396.259K / 525.823K |
Day Range | 2.120 - 2.285 |
52 Wk Range | 1.150 - 3.620 |
Market Cap | $286.844M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 63 |
Short Interest | 2.16% |
Days to Cover | 5.09 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Compass Therapeutics (NASDAQ: CMPX) through any online brokerage.
Other companies in Compass Therapeutics’s space includes: bluebird bio (NASDAQ:BLUE), Inovio Pharmaceuticals (NASDAQ:INO), Opthea (NASDAQ:OPT), Monte Rosa Therapeutics (NASDAQ:GLUE) and Century Therapeutics (NASDAQ:IPSC).
The latest price target for Compass Therapeutics (NASDAQ: CMPX) was reported by HC Wainwright & Co. on Thursday, August 3, 2023. The analyst firm set a price target for 10.00 expecting CMPX to rise to within 12 months (a possible 344.44% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Compass Therapeutics (NASDAQ: CMPX) is $2.25 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Compass Therapeutics.
Compass Therapeutics’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Compass Therapeutics.
Compass Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.